Expert consensus on the management of chronic lymphocytic leukaemia in Asia

Clin Exp Med. 2023 Oct;23(6):2895-2907. doi: 10.1007/s10238-023-01007-2. Epub 2023 Feb 16.


In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL from an Asian population perspective. This consensus guideline aims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian population and other countries with a similar socio-economic profile. The following recommendations are based on a consensus by experts and an extensive literature review and contribute towards uniform patient care in Asia.

Keywords: Asia; BTK inhibitors; Bcl-2 inhibitors; Chronic lymphocytic leukaemia; Treatment.

Publication types

  • Letter

MeSH terms

  • Asia / epidemiology
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell* / epidemiology
  • Leukemia, Lymphocytic, Chronic, B-Cell* / therapy